[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_16345 

# __Unclear efficacy of protection against re-infections in people with and without symptoms at their initial sars-cov-2 infection__

## Articles mentionning the risk

* [Pilz_contributions_2022](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_608.md)

## Mitigations of this risk

* [Further evaluation of the efficacy of protection against re-infections in symptomatic and asymptomatic individuals](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_18288.md)

## Name of the risk

Uncertainty in determining the level of protection provided by natural immunity

## People affected by this risk

* [Individuals with a history of sars-cov-2 infection](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_13147.md)

## Stakeholders who can mitigate this risk

* [Health organizations](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)
* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_422.md)

## Technologies linked to the risk

* [Data analysis tools](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_552.md)
* [Research studies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1814.md)

## This Risk belongs to this RiskGroup

* [Public health risks](https://github.com/mm80843/T3.5/blob/pages/RiskGroup/PBN__RiskGroup_3.md)

## This Risk belongs to this RiskSubgroup

* [Lack of effective medical solutions](https://github.com/mm80843/T3.5/blob/pages/RiskSubgroup/PBN__RiskSubgroup_37.md)

